A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy

Lynn K.H. Tran, Paul M.H. Tran, David P. Mysona, Sharad B. Purohit, Emily Myers, Won Sok Lee, Boying Dun, Duo Xu, Haitao Liu, Diane Hopkins, John Nechtman, Chris L. Scelsi, Pardeep K. Mittal, Daniel Kleven, John J. Wallbillich, Bunja Rungruang, Sharad Ghamande, Jin Xiong She

Research output: Contribution to journalArticle

Abstract

Objectives: To develop a transcriptomic signature capable of predicting overall survival (OS) for uterine serous carcinoma (USC). Methods: RNAseq data for 58 USC patients were obtained from TCGA. Expression of 73 candidate genes was measured for 67 Augusta University (AU) samples using NanoString technology. Results: Analysis of the TCGA RNAseq data identified 73 genes that individually predict prognosis for USC patients and an elastic net model with all 73 genes (USC73) distinguishes a good OS group with low USC73 score from a poor OS group with high USC73 score (5-year OS = 83.3% and 13.3% respectively, HR = 40.1; p = 3 × 10−8). This finding was validated in the independent AU cohort (HR = 4.3; p = 0.0004). The poor prognosis group with high USC73 score consists of 37.9% and 32.8% of patients in the TCGA and AU cohort respectively. USC73 score and pathologic stage independently contribute to OS and together provide the best prognostic value. Early stage, low USC73 patients have the best prognosis (5-year OS = 85.1% in the combined dataset), while advanced stage, high USC73 patients have the worst prognosis (5-year OS = 6.4%, HR = 30.5, p = 1.2 × 10−12). Consistent with the observed poor survival, primary cell cultures from high USC73 patients had higher proliferation rate and cell cycle progression; and high USC73 patients had lower rates of complete response to standard therapy. Conclusions: The USC73 transcriptomic signature and stage independently predict OS of USC patients and the best prediction is achieved using USC73 and stage. USC73 may also serve as a therapeutic biomarker to guide patient care.

Original languageEnglish (US)
JournalGynecologic Oncology
DOIs
StateAccepted/In press - Jan 1 2020

    Fingerprint

Keywords

  • Cell proliferation
  • Gene expression
  • Prognostic biomarker
  • Serous
  • Uterine

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Tran, L. K. H., Tran, P. M. H., Mysona, D. P., Purohit, S. B., Myers, E., Lee, W. S., Dun, B., Xu, D., Liu, H., Hopkins, D., Nechtman, J., Scelsi, C. L., Mittal, P. K., Kleven, D., Wallbillich, J. J., Rungruang, B., Ghamande, S., & She, J. X. (Accepted/In press). A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy. Gynecologic Oncology. https://doi.org/10.1016/j.ygyno.2020.02.015